$1.94
+0.3
(+18.29%)▲
9.28%
Downside
Day's Volatility :10.66%
Upside
1.52%
76.19%
Downside
52 Weeks Volatility :89.5%
Upside
55.91%
Period | Mawson Infrastructure Group Inc | Index (Russel 2000) |
---|---|---|
3 Months | 119.16% | 0.0% |
6 Months | 70.18% | 0.0% |
1 Year | 207.94% | 0.0% |
3 Years | -97.59% | -27.4% |
Market Capitalization | 30.4M |
Book Value | $0.25 |
Earnings Per Share (EPS) | -3.66 |
Wall Street Target Price | 3.0 |
Profit Margin | -107.21% |
Operating Margin TTM | -38.0% |
Return On Assets TTM | -32.47% |
Return On Equity TTM | -197.88% |
Revenue TTM | 57.2M |
Revenue Per Share TTM | 3.41 |
Quarterly Revenue Growth YOY | 24.3% |
Gross Profit TTM | 36.7M |
EBITDA | -10.3M |
Diluted Eps TTM | -3.66 |
Quarterly Earnings Growth YOY | -0.98 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 54.64%
Sell
Neutral
Buy
Mawson Infrastructure Group Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mawson Infrastructure Group Inc | 63.03% | 70.18% | 207.94% | -97.59% | -96.6% |
Interactive Brokers Group, Inc. | 15.56% | 42.43% | 110.38% | 133.12% | 268.83% |
Morgan Stanley | 22.16% | 37.27% | 74.14% | 31.4% | 170.22% |
Tradeweb Markets Inc. | -3.23% | 16.23% | 39.45% | 34.89% | 209.36% |
Charles Schwab Corp., The | 17.83% | 0.28% | 37.15% | -7.26% | 74.14% |
Goldman Sachs Group, Inc., The | 20.49% | 34.29% | 83.97% | 45.95% | 166.91% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mawson Infrastructure Group Inc | NA | NA | NA | 0.0 | -1.98 | -0.32 | NA | 0.25 |
Interactive Brokers Group, Inc. | 23.47 | 23.62 | 11.75 | 6.86 | 0.22 | 0.02 | 0.01 | 38.25 |
Morgan Stanley | 17.64 | 17.89 | 3.41 | 7.33 | 0.1 | 0.01 | 0.03 | 56.8 |
Tradeweb Markets Inc. | 61.09 | 62.03 | 2.97 | 2.9 | 0.08 | 0.07 | 0.0 | 26.74 |
Charles Schwab Corp., The | 27.72 | 27.75 | 1.15 | 3.12 | 0.12 | 0.01 | 0.01 | 19.01 |
Goldman Sachs Group, Inc., The | 14.99 | 15.46 | 3.56 | 36.73 | 0.1 | 0.01 | 0.02 | 327.61 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mawson Infrastructure Group Inc | Buy | $26.9M | -96.6% | NA | -107.21% |
Interactive Brokers Group, Inc. | Buy | $65.1B | 268.83% | 23.47 | 14.42% |
Morgan Stanley | Hold | $189.9B | 170.22% | 17.64 | 19.21% |
Tradeweb Markets Inc. | Buy | $27.7B | 209.36% | 61.09 | 27.52% |
Charles Schwab Corp., The | Buy | $129.8B | 74.14% | 27.72 | 27.47% |
Goldman Sachs Group, Inc., The | Buy | $165.4B | 166.91% | 14.99 | 24.65% |
Insights on Mawson Infrastructure Group Inc
Revenue is down for the last 2 quarters, 18.77M → 13.11M (in $), with an average decrease of 30.2% per quarter
Netprofit is up for the last 2 quarters, -19.76M → -9.61M (in $), with an average increase of 105.5% per quarter
In the last 3 years, Interactive Brokers Group, Inc. has given 132.6% return, outperforming this stock by 230.0%
Vident Advisory, LLC
Vanguard Group Inc
Geode Capital Management, LLC
State Street Corp
UBS Group AG
Millennium Management LLC
wize pharma, inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including des. wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as lo2a, a drug developed for the treatment of des, and other ophthalmological illnesses, including cch and sjögren's syndrome (sjögren's). lo2a is currently registered and marketed by its inventor in germany and switzerland for the treatment of des, in hungary for the treatment of des, cch and sjögren's and in the netherlands for the treatment of des and sjögren's. wize's strategy involves engaging local or multinational distributors to handle the distribution of lo2a. wize has finished a phase ii trial of lo2a for patients with cch and is currently conducting a phase iv study for lo2a for des in patients with sjögren's.
Organization | Mawson Infrastructure Group Inc |
Employees | 30 |
CEO | Mr. Rahul Mewawalla |
Industry | Miscellaneous |
Cactus Acquisition Corp 1 Ltd
$1.94
+18.29%
Rigel Resource Acquisition Corp
$1.94
+18.29%
Everi Holdings Inc
$1.94
+18.29%
Anfield Us Equity Sector Rotation Etf
$1.94
+18.29%
3edge Dynamic Fixed Income Etf
$1.94
+18.29%
Direxion Daily Csi 300 China A Share 2x Shares Etf
$1.94
+18.29%
Dfa Dimensional Us Real Estate Etf
$1.94
+18.29%
Sow Good Inc
$1.94
+18.29%
Uscb Financial Holdings Inc
$1.94
+18.29%